Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2005-12-16
2010-10-26
Skelding, Zachary (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C514S866000
Reexamination Certificate
active
07820168
ABSTRACT:
The instant specification provides methods of treatment for inflammatory and autoimmune disorders of the metabolic system. The instant specification also provides methods of diagnosis.
REFERENCES:
patent: 5827513 (1998-10-01), Bond et al.
patent: 6706264 (2004-03-01), Leonard et al.
patent: 2003/0017617 (2003-01-01), Chirica et al.
patent: 2003/0206874 (2003-11-01), Doyle et al.
patent: 2004/0213761 (2004-10-01), Bowman et al.
patent: 2004/0258686 (2004-12-01), Chirica et al.
patent: WO 01/18051 (2001-03-01), None
patent: WO 2004042009 (2004-05-01), None
patent: WO 2004/071517 (2004-08-01), None
patent: WO 2004/081190 (2004-09-01), None
patent: WO 2004/101750 (2004-11-01), None
patent: WO 2005010044 (2005-02-01), None
Gerich et al., MedGenMed. Aug. 26, 2004;6(3 Suppl).
Atkinson et al, Nature, 1999, V.5, pp. 601-604.
Whitty et al., Chem. Biol. Apr. 1999;6(4):R107-18.
Casset et al., Biochemical and Biophysical Research Communications, 307:198-205, 2003.
Monnet et al., J. Biol. Chem. 274 (1999) 3789-3796.
Rothe et al., Diabetologia. Jun. 1997;40(6):641-6.
Bergholdt et al., J Med Genet. Apr. 2004;41(4):e39.
Larger et al., Diabetes Care. Jul. 2004;27(7):1842-3.
The Merck Manual of Diagnosis and Therapy, (Mark Beers and Robert Berkow, eds., Published by Merck Research Laboratories, 17th ed., 1999, pp. 165-171.
“The Diabetes Prevention Trial Type I Diabetes Study Group”, N Engl J Med. May 30, 2002;346(22):1685-91.
Kobayashi et al., Diabetes. May 1996;45(5):622-6.
Goldsby et al., Immunology, 5th Ed., W.H. Freeman and Co., pp. 462-463 (2002).
Webster's New World Dictionary, Third College Edition, 1988, see p. 1067.
Jovanovic et al., J Immunol. Apr. 1, 1998;160(7):3513-21.
Zozulinska et al., Diabetologia. Jan. 1999;42(1):117-8.
Chen et al., Diabetologia. Mar. 2001;44(3):325-32.
Rabinovitch et al., Diabetes Metab Rev. Jun. 1998;14(2):129-51.
Tennenberg et al., Arch Surg. Nov. 1999;134(11):1229-33.
Vukkadapu et al., Physiol Genomics. Apr. 14, 2005;21(2):201-11.
Martin-Orozco et al., Eur J Immunol. Jan. 2009;39(1):216-24.
Jain et al., J Exp Med. Jan. 21, 2008;205(1):207-18.
Emamaullee et al., Diabetes. Jun. 2009;58(6):1302-11.
Cua, et al. (2003)Nature421(6924):744-748 “Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain”.
Elkins, et al. (2002)Infection Immunity70(4):1936-1948 “In Vivo Clearance of an Intracellular Bacterium,Francisella tularensisLVS, Is Dependent on the p40 Subunit of Interleukin-12 (IL-12) but Not on IL-12 p70”.
Frucht (2002)Sci STKE114:pe1 (pp. 1-3) “IL-23: a cytokine that acts on memory T cells”.
Hutchings et al., (1990)J. Autoimmun. Issue 3, Suppl. 1, pp. 101-109 “The involvement of Ly2+ T cells in beta cell destruction”.
Lund et al., (1990)Nature345(6277):727-729 “Prevention of insulin-dependent diabetes mellitus in non-obese diabetic mice by transgenes encoding modified I-Aβ-chain or normal I-Eα-chain”.
Murphy, et al. (2003)J. Exp. Med. 198(12):1951-1957 “Divergent Pro- and Antiinflammatory Roles for II-23 and IL-12 in Jiont Autoimmune Inflammation”.
Oppmann, et al. (2000)Immunity13(5):715-725 “Novel p19 Protein Engages IL-12p40 to Form a Cytokine, IL-23, with Biological Activites Similar as Well as Distinct from IL-12”.
Parham, et al. (2002)J. Immunol. 168:5699-5708 “A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rβ1 and a novel cytokine receptor subunit, IL-23R”.
Slattery et al., (1990)Nature345:724-726 “Prevention of diabetes in non-obese diabetic I-Ak transgenic mice”.
Trinchieri, et al. (2003)Immunity19(5):641-644 “The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses”.
Wiekowski, et al. (2001)J. Immunol.166(12):7563-7570 “Ubiquitous transgenic expression of the IL-23 subunit p19 induces multiorgan inflammation, runting, infertility, and premature death”.
Aggarwal et al. (2003)J. Biol. Chem.278:1910-1914 “Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of Interleukin-17”.
Feili-Hariri et al. (2002)Eur. J. Immunol. 32:2021-2030 “Regulatory Th2 response induced following adoptive transfer of dendritic cells in prediabetic NOD mice”.
Cua Daniel J.
Kastelein Robert A.
Bellomy Gregory R.
Schering Corporation
Skelding Zachary
LandOfFree
Treatment of diabetes using antibodies to IL-23, IL-23... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of diabetes using antibodies to IL-23, IL-23..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of diabetes using antibodies to IL-23, IL-23... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4169032